Of note, no complete knowledge of our enemy, the highly aggressive KL NSCLC, may be reached without considering, both in preclinical studies and in clinical trials, the large amount of wild-type LKB1 tumors that partially or completely lost LKB1 activity: the so called “LKB1less tumors”. Here, STK11 is linked to non-small cell lung carcinoma.